Funder
Ministere de l'economie et de l'innovation
Canadian Heart Failure Society
Quebec Heart Failure Society
Université du Québec à Trois-Rivières
Publisher
Springer Science and Business Media LLC
Reference86 articles.
1. Association Canadienne du Médicament Générique. Les faits. 2017. http://generiquescanadiens.ca/les-faits/medicaments-generiques/. Accessed 27 septembre 2017
2. Santé Canada. Ligne directrice - Normes en matière d’études de biodisponibilités comparatives: Formes pharmaceutiques de médicaments à effets systémiques. 2018. https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/biodisponibilite-bioequivalence/normes-matiere-etudes-biodisponibilite-comparatives-formes-pharmaceutiques-medicaments-effets-systemiques.html. Accessed 29 octobre 2018
3. Leclerc J, Blais C, Rochette L, et al. Did Generic Clopidogrel Commercialization Affect Trends of ER Consultations and Hospitalizations in the Population Treated with Clopidogrel? Drugs Aging. 2019.
4. Leclerc J, Blais C, Rochette L, et al. Trends in hospital visits for generic and brand-name warfarin users in Quebec, Canada; a population-based time series analysis. Am J Cardiovasc Drugs. 2018;19(3):287–97.
5. Leclerc J, Blais C, Rochette L, et al. Impact of the commercialization of three generic angiotensin II receptor blockers on adverse events in Quebec, Canada: a population-based time series analysis. Circ Cardiovasc Qual Outcomes. 2017;10:1–9.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献